Electroporation is the wave of the future for transdermal drug delivery, according to Parexel’s Ravi Harapanhalli.
The contract research organisation’s (CRO) principle consultant for late stage development told in-PharmaTechnologist that, with recent developments, it is an exciting time for delivery via the skin.
“The industry is at a stage where hydrophilic drugs, peptides, heparin fragments and even proteins can be delivered through the skin,” said Harapanhalli.
“This is a big development in the design and control of drugs.”
Put to Harapanhalli the question of the next ‘big thing’ in the research area, he said that electroporation shows promise.
He added: “I must say electroporosis – passage of low voltage electric current through the patch (is promising).
“The method is commonly used in development at the moment, and there are some approved products already using that technology and they are able to achieve better controlled and more effective delivery.”